Novo, Roche, GlaxoSmithKline and Novartis, all of which participated in a $41m round for Alios in April, exited the pharmaceutical company, which was bought by Johnson & Johnson.

The pharmaceutical company, backed by Allergan and Boehringer Ingelheim, raised the cash after $109m of equity funding.

Adaptimmune, which focuses on the use of T-cell therapy to treat cancer and infectious diseases, has completed a huge series A round to expand its clinical trials.

WiserTogether has raised $9m in a series B round that featured Merck's corporate venturing unit, and which will be used to scale its operations.

Silarus Therapeutics and Thyritiope Biosciences are the second and third companies to emerge from the firms' $495m life sciences incubation partnership.

Cancer diagnostics company Inivata, which works with technology spun-out from Cancer Research UK, has received $6m in its first external venture round.

Ruga is licensing research that could prevent cancer from spreading throughout the body.

Takeda Pharmaceuticals is buying a minority share in the accelerator.

Parkinson's disease treatment company Civitas has been bought by Acorda for $525m, weeks after it raised a $55m series C round and filed for an IPO.